How Hormone Therapy Helps Regulate Menopause: What to Watch For

Introduction: Menopause Is Natural, But Suffering Through It Does Not Have to Be

Every woman will experience menopause. For some, the transition is manageable. For many others, it is profoundly disruptive, affecting sleep, mood, relationships, sexual health, cognitive function, bone density, cardiovascular health, and day-to-day quality of life in ways that are significant and real.

Yet despite decades of research, menopause remains one of the most under-discussed and undertreated transitions in women’s health. A landmark survey published in Menopause (2019) by the Menopause Society found that more than 73% of women with moderate-to-severe menopause symptoms had never been treated and that many had not even been asked about their symptoms by their healthcare provider.

That gap in care is not acceptable. And it is precisely why understanding your options in particular hormone therapy (HT), the most effective and extensively studied treatment for menopause symptoms  is so important.

This guide covers what hormone therapy is, how it works, what symptoms it addresses most effectively, what the science truly says about its safety, what warning signs to monitor during treatment, and how to make an informed decision with your provider about whether it is right for you.

Understanding Menopause: What Is Actually Happening in Your Body

Before exploring hormone therapy, it helps to understand the physiological changes that define menopause and drive its symptoms.

Menopause is defined as the permanent cessation of menstruation, confirmed after 12 consecutive months without a menstrual period, resulting from the natural decline and eventual exhaustion of ovarian follicles. The average age of natural menopause in the United States is 51.4 years, with a normal range from 45 to 55.

Perimenopause is the transitional phase leading up to menopause. Typically begins 4 to 10 years before the final menstrual period and is characterized by hormonal fluctuations, irregular cycles, and the emergence of classic menopause symptoms. Many women are surprised to learn that their most disruptive symptoms often occur during perimenopause, before menstruation actually stops.

The hormonal changes driving menopause:

The ovaries are the primary source of estradiol (the dominant form of estrogen in reproductive years) and progesterone. As ovarian follicle reserves decline, estradiol and progesterone levels fall dramatically. This hormonal withdrawal affects virtually every organ system in the body because estrogen receptors are found throughout the brain, heart, bones, skin, vagina, bladder, liver, and more.

The hypothalamus is the brain’s hormonal control center, it responds to falling estrogen by increasing output of gonadotropin-releasing hormone (GnRH), which drives elevated levels of follicle-stimulating hormone (FSH) and luteinizing hormone (LH). These elevated gonadotropins are the basis of blood tests used to confirm menopausal status.

A pivotal review published in The Lancet summarized the physiological impact of estrogen withdrawal across multiple organ systems confirming that declining estrogen is not merely a reproductive event but a systemic hormonal transition with wide-ranging health consequences extending well beyond hot flashes.

The Symptoms of Menopause: What to Watch For

Menopause symptoms vary dramatically in type, severity, and duration. Understanding the full spectrum  and recognizing which symptoms may signal a need for treatment  is the foundation of proactive menopause management.

Vasomotor Symptoms (Hot Flashes and Night Sweats)

The hallmark of menopause. Hot flashes are sudden sensations of intense warmth often beginning in the chest, neck, or face accompanied by flushing, perspiration, and heart palpitations, followed by chills as the body temperature recalibrates. They typically last 2–4 minutes but can recur dozens of times per day.

Night sweats are hot flashes occurring during sleep, often severe enough to require changing clothing or bedding and causing significant sleep fragmentation and daytime fatigue.

According to the Study of Women’s Health Across the Nation (SWAN) , one of the largest longitudinal menopause studies conducted, approximately 80% of women experience vasomotor symptoms during the menopausal transition, with 25–30% rating them as severely disruptive. Crucially, the SWAN study found that the median duration of vasomotor symptoms is 7.4 years  and in some women, symptoms persist for 10 years or longer. This is not a brief transitional inconvenience; for many women, it is a prolonged health burden that significantly affects daily functioning.

Sleep Disturbances

Insomnia, frequent nighttime awakening, and non-restorative sleep are among the most commonly reported  and most debilitating menopause symptoms. Sleep disruption is directly driven by nocturnal vasomotor symptoms, but also occurs independently through estrogen’s direct effects on sleep architecture.

A study published in the Journal of Clinical Sleep Medicine (2015) found that perimenopausal and postmenopausal women had significantly higher rates of insomnia, poorer sleep quality, and greater daytime fatigue compared to premenopausal women  with vasomotor symptoms being the strongest predictor of sleep disturbance severity.

Genitourinary Syndrome of Menopause (GSM)

One of the most underreported yet impactful aspects of menopause is the genitourinary syndrome of menopause (GSM),  formerly known as vulvovaginal atrophy. GSM encompasses a constellation of symptoms resulting from estrogen deficiency in the genital and urinary tissues:

• Vaginal dryness, burning, and irritation
• Painful intercourse (dyspareunia)
• Recurrent urinary tract infections (UTIs)
• Urinary urgency, frequency, and stress incontinence
• Reduced vaginal lubrication and elasticity

Unlike vasomotor symptoms, which often improve over time, GSM is progressive  worsening without treatment as estrogen deficiency continues. A study in Menopause (2014) by Nappi and Kokot-Kierepa found that GSM affected approximately 45% of postmenopausal women and significantly impaired sexual function and quality of life, yet fewer than 25% had discussed it with their healthcare provider.

Mood Changes: Anxiety, Depression, and Irritability

The neurological and psychological impact of menopause is profound and often underrecognized. Estrogen has direct neuromodulatory effects in the brain  influencing serotonin, dopamine, and norepinephrine pathways that regulate mood, motivation, and emotional regulation.

A landmark study published in the Archives of General Psychiatry (2006) by Cohen et al. found that women were 2–4 times more likely to experience a major depressive episode during the perimenopause transition compared to before  independent of prior depression history, life stressors, and sleep disturbance.

Additional mood and neurological symptoms include:

• Anxiety and panic attacks — especially in women with no prior anxiety history
• Irritability, emotional lability, and mood swings
• Brain fog — difficulty with concentration, memory, word retrieval, and multitasking (known as menopause-associated cognitive decline)
• Reduced motivation and loss of enjoyment in activities

Bone Loss (Osteopenia and Osteoporosis)

Estrogen is the primary regulator of bone remodeling in women. In the years surrounding menopause, bone density can decline at a rate of 2–3% per year, a loss that accelerates dramatically in the early postmenopausal years. Over time, this leads to osteopenia and ultimately osteoporosis, a condition characterized by fragile, fracture-prone bones.

The National Osteoporosis Foundation estimates that 1 in 2 women over 50 will experience an osteoporosis-related fracture in their lifetime. Hip fractures, in particular, carry a mortality rate of up to 24% within the first year in older women,  making bone health a critical long-term consequence of estrogen loss that warrants proactive management.

Cardiovascular Changes

Estrogen has important cardioprotective properties: it supports healthy lipid profiles (raising HDL, lowering LDL), maintains arterial flexibility and endothelial function, and reduces inflammation in the vascular wall. After menopause, as estrogen levels fall, women’s cardiovascular risk profile shifts substantially and by their 60s, women’s rates of heart disease approach and eventually exceed those of men.

A comprehensive review published in Circulation (2020) by El Khoudary et al. confirmed that the menopausal transition is an independent risk period for accelerated cardiovascular change with increases in blood pressure, arterial stiffness, LDL cholesterol, and abdominal adiposity that begin in perimenopause.

Sexual Health Changes

Beyond GSM, menopause affects sexual desire, arousal, and satisfaction through multiple pathways: declining testosterone (which also falls during menopause), reduced genital blood flow, altered brain reward pathways, and the psychological impact of fatigue, mood changes, and body image concerns. Studies consistently show that sexual function declines significantly during the menopausal transition for many women, a change that affects both personal wellbeing and relationships.

What Is Hormone Therapy? Understanding the Options

Hormone therapy (HT)  also referred to as hormone replacement therapy (HRT), menopausal hormone therapy (MHT), or estrogen therapy  involves administering hormones to replace or supplement those declining during menopause. It is the most effective available treatment for menopausal symptoms and the treatment recommended as first-line therapy by virtually every major menopause and women’s health organization in the world, including:

• The Menopause Society (formerly NAMS)
• The British Menopause Society (BMS)
• The European Menopause and Andropause Society (EMAS)
• The International Menopause Society (IMS)
• The American College of Obstetricians and Gynecologists (ACOG)

The Types of Hormone Therapy

Estrogen-Only Therapy (ET) Prescribed for women who have had a hysterectomy (uterus removed). Estrogen alone, without the addition of progesterone, is the simplest and most effective regimen for symptom control. Available in multiple formulations:

• Oral tablets (e.g., conjugated equine estrogen, estradiol)
• Transdermal patches (estradiol — released through the skin continuously)
• Transdermal gels and sprays (applied daily to the skin)
• Vaginal ring (Estring — for local GSM treatment with minimal systemic absorption)

Combined Estrogen-Progestogen Therapy (EPT) For women with an intact uterus. Progesterone (or a synthetic progestin) must be added to estrogen to protect the uterine lining (endometrium) from the stimulating effects of unopposed estrogen, which can cause endometrial hyperplasia and increase the risk of endometrial cancer.

Combined regimens include:

• Sequential (cyclic) therapy — estrogen daily plus progestogen for 12–14 days per month, producing a regular “withdrawal bleed”
• Continuous combined therapy — both hormones taken daily, with the goal of no monthly bleeding (preferred by most postmenopausal women)

Progestogen types used in combined therapy:

• Micronized progesterone (Prometrium, Utrogestan) — bioidentical progesterone most closely resembling the body’s own hormone, with a favorable safety and tolerability profile
• Synthetic progestins (medroxyprogesterone acetate, norethisterone, dydrogesterone) — effective but with different risk profiles depending on type

Local (Vaginal) Estrogen Low-dose estrogen delivered directly to the vaginal tissues in the form of creams, pessaries (tablets), or a vaginal ring. Primarily addresses GSM symptoms (dryness, discomfort, urinary symptoms) with minimal systemic absorption making it appropriate for many women who cannot or prefer not to use systemic HT. Local vaginal estrogen does not require concurrent progesterone as the systemic absorption is negligible.

Bioidentical Hormone Therapy “Bioidentical” refers to hormones chemically identical in structure to those produced by the human body, specifically 17β-estradiol and micronized progesterone. These are available in FDA-approved formulations (e.g., Vivelle-Dot patch, Climara patch, Prometrium capsules) as well as in compounded preparations. The Menopause Society’s position statement (2022) emphasizes that FDA-approved bioidentical hormones have well-established safety and efficacy data, while compounded bioidenticals lack this evidence and have variable quality and dosing.

How Hormone Therapy Regulates Menopause: The Evidence

Vasomotor Symptom Relief

Hormone therapy is the gold standard treatment for hot flashes and night sweats,  more effective than any other pharmacological or non-pharmacological intervention studied.

A comprehensive meta-analysis published in The Cochrane Database of Systematic Reviews (2015) by MacLennan et al.  analyzing 24 randomized controlled trials involving over 3,000 women  found that estrogen therapy reduced hot flash frequency by 75% compared to placebo, with a corresponding dramatic improvement in hot flash severity. No other treatment approaches this level of efficacy.

The clinical impact is profound: women who previously experienced 10–15 hot flashes per day, each disrupting sleep and daily activity, often report reduction to 2–3 mild episodes,  a transformation in daily functioning that is difficult to overstate.

Sleep Quality Improvement

By eliminating or significantly reducing nocturnal vasomotor symptoms, hormone therapy produces substantial improvements in sleep quality, sleep duration, and next-day alertness. A randomized controlled trial published in Menopause (2014) found that HT significantly improved sleep architecture, reducing nighttime awakenings, increasing slow-wave sleep, and improving subjective sleep quality compared to placebo.

GSM Treatment and Sexual Health

Systemic hormone therapy effectively addresses GSM symptoms as part of its broad hormonal restoration. For women whose primary concern is vaginal dryness and dyspareunia, low-dose local vaginal estrogen is the preferred, evidence-based treatment  restoring vaginal pH, tissue thickness, lubrication, and elasticity with minimal systemic effects.

A randomized trial published in Menopause (2018) confirmed that local vaginal estradiol significantly improved vaginal dryness, dyspareunia, and urinary urgency in postmenopausal women, with patient satisfaction rates exceeding 85%.

Mood and Cognitive Benefits

Multiple randomized trials and observational studies support estrogen therapy’s positive effects on mood, particularly in perimenopausal women. A pivotal trial published in JAMA Psychiatry (2018) by Gordon et al. found that transdermal estradiol significantly reduced depressive symptoms in perimenopausal and early postmenopausal women compared to placebo an effect that was independent of vasomotor symptom improvement, suggesting a direct neurological benefit.

Research on cognitive function is similarly encouraging, particularly for women who initiate hormone therapy during the “critical window” within 10 years of menopause onset. A prospective study published in Neurology (2017) found that women who used hormone therapy during the perimenopause and early postmenopause had significantly better performance on verbal memory and executive function tests compared to untreated women.

Bone Protection

Hormone therapy is one of the most effective interventions available for preventing postmenopausal bone loss. Multiple randomized controlled trials including the Women’s Health Initiative (WHI) bone density substudy confirmed that both estrogen-only and combined HT significantly increase bone mineral density and reduce fracture risk.

The WHI bone data, published in JAMA (2003) by Cauley et al., found that women taking combined HT had a 24% reduction in hip fractures and a 34% reduction in vertebral fractures compared to placebo a finding of enormous clinical significance given the morbidity and mortality associated with osteoporotic fractures.

Cardiovascular Effects: The “Timing Hypothesis”

The cardiovascular effects of hormone therapy are among the most discussed and most misunderstood aspects of HT, largely due to misinterpretation of the original WHI study findings.

The WHI, published in JAMA (2002), initially reported increased cardiovascular risk with combined HT, a finding that led to a dramatic, and in retrospect partially unjustified, decline in HT prescribing worldwide. Subsequent reanalysis of the WHI data and multiple other studies revealed a critical nuance: age and time since menopause matter enormously.

The “timing hypothesis” or “window of opportunity” — now supported by the WHI reanalysis (Rossouw et al., 2007), the Kronos Early Estrogen Prevention Study (KEEPS), the Early versus Late Intervention Trial with Estradiol (ELITE), and multiple observational cohorts demonstrates that:

• Women who initiate HT within 10 years of menopause onset or before age 60 show cardiovascular benefit or neutral effects, not harm. 
• Women who initiate HT more than 10 years after menopause or after age 60 particularly those who already have established atherosclerosis,  may not benefit cardiovascularly and may face slightly elevated risk. 

A landmark meta-analysis published in The Lancet (2019) by the Collaborative Group on Hormonal Factors in Breast Cancer reaffirmed these timing nuances and reinforced that for recently menopausal women under 60, the cardiovascular risk-benefit profile of HT is generally favorable.

The current position of the Menopause Society (2022) states that for healthy women under 60 or within 10 years of menopause onset, the benefits of HT outweigh the risks, a consensus position endorsed by all major menopause organizations globally.

Hormone Therapy and Breast Cancer Risk: Putting the Evidence in Context

Breast cancer risk is the concern most frequently cited by women  and providers when discussing hormone therapy. It deserves a clear, honest, evidence-based discussion.

The most important findings from the research:

Estrogen-only therapy in women who have had a hysterectomy is associated with no increase in breast cancer risk at standard doses for up to 7 years of use, according to the WHI estrogen-only trial published in JAMA (2004). In fact, that study found a modest (though not statistically significant) reduction in breast cancer diagnosis, a finding that has been replicated in observational studies.

Combined estrogen-progestogen therapy is associated with a small increase in breast cancer risk with long-term use (beyond 5 years), primarily attributed to the progestogen component. A study published in The Lancet (2019) found that the absolute increase in risk was approximately 1 extra case per 1,000 women per year of use comparable to the risk associated with having 1–2 alcoholic drinks per day, being overweight, or being sedentary.

Type of progestogen matters: Micronized progesterone (bioidentical progesterone) has been shown in multiple European observational studies  including the large E3N French cohort  to be associated with a lower breast cancer risk than synthetic progestins. A study published in Climacteric (2020) found that combined therapy using micronized progesterone and estradiol was associated with significantly lower breast cancer risk compared to regimens using synthetic progestins  a finding that is increasingly influencing clinical practice toward the use of bioidentical progesterone.

Route of administration: Transdermal estradiol (patch, gel, spray) does not undergo first-pass metabolism in the liver and is associated with a lower risk of venous thromboembolism (blood clots) compared to oral estrogen an important safety consideration, particularly for women with cardiovascular risk factors.

Duration and absolute risk: The absolute excess risk of breast cancer from combined HT, even with synthetic progestins is small in the context of individual decision-making. The Menopause Society (2022) position statement emphasizes that for women under 60 with significant menopause symptoms, the absolute increase in breast cancer risk from short-to-medium term combined HT is modest and must be weighed against the substantial quality-of-life benefits of treatment a decision that should be made individually with full information, not withheld as a categorical refusal.

What to Watch For During Hormone Therapy: Monitoring and Safety

For women on hormone therapy, regular monitoring by an experienced provider is essential. Knowing what symptoms to report  and what warning signs to watch for  ensures that therapy remains safe, effective, and well-tolerated.

Expected and Common Side Effects in the First 3 Months

As the body adjusts to hormone therapy, transient side effects are common and typically resolve within 8–12 weeks:

• Breast tenderness or fullness — one of the most common early side effects; usually resolves with dose adjustment or time
• Bloating and water retention — more common with oral estrogen; may improve with transdermal delivery
• Nausea — particularly with oral estrogen tablets; usually improves when taken with food or switching to transdermal
• Mood fluctuations — temporary, as the body adapts to hormonal change
• Breakthrough or irregular bleeding — common in the first 3–6 months of continuous combined therapy; persistent or heavy bleeding after 6 months requires evaluation
• Headaches — some women experience headaches with estrogen fluctuations; transdermal delivery (producing stable blood levels) often helps

Warning Signs That Require Prompt Evaluation

While serious adverse events on HT are uncommon, certain symptoms require immediate medical attention:

Call your doctor immediately or go to the ER if you experience:

• Sudden chest pain, chest tightness, or shortness of breath — could indicate deep vein thrombosis (DVT) or pulmonary embolism (PE)
• Sudden severe headache — unlike any headache you have had before
• Vision changes — blurred vision, double vision, or sudden vision loss
• Leg pain, swelling, warmth, or redness — possible deep vein thrombosis
• Sudden weakness, numbness, speech difficulty, or facial drooping — stroke warning signs
• Unusual breast changes — new lump, skin dimpling, nipple discharge

Schedule a prompt (non-emergency) appointment if you experience:

• Abnormal vaginal bleeding — particularly heavy bleeding or bleeding that occurs after being period-free for 12+ months on a continuous regimen; this requires investigation to exclude endometrial pathology
• Breast pain that is new, persistent, or severe
• Persistent headaches or migraines that are new or worsening
• Symptoms that are not improving after 3 months on therapy — may indicate dose adjustment is needed
• Significant mood changes — depression, anxiety, or irritability that worsens rather than improves on HT

Ongoing Monitoring While on Hormone Therapy

Women on hormone therapy should maintain the following:

Annual well-woman visits with discussion of ongoing symptom control, side effect profile, and risk-benefit reassessment. The decision to continue HT should be revisited at least annually with your provider.

Annual mammography — as recommended for all women 40 and older, and particularly important for women on combined HT.

Blood pressure monitoring — oral estrogen can modestly elevate blood pressure in susceptible women; transdermal delivery has a neutral blood pressure profile.

Bone density assessment (DEXA scan) — recommended at baseline at menopause and every 1–2 years thereafter to monitor the protective effects of HT on bone.

Lipid panel and metabolic assessment — particularly for women with cardiovascular risk factors, to track the effects of therapy on cholesterol, triglycerides, and glucose.

Pelvic examination and cervical screening (Pap smear) — per standard recommendations.

Liver function — oral estrogen undergoes first-pass hepatic metabolism; liver function should be monitored in women with hepatic risk factors or on oral therapy long-term.

Who Is a Good Candidate for Hormone Therapy?

Most healthy women experiencing significant menopause symptoms are candidates for hormone therapy. The strongest indications include:

• Women under 60 or within 10 years of menopause onset with moderate-to-severe vasomotor symptoms
• Women with premature ovarian insufficiency (POI) or early menopause (before age 45) — for whom hormone therapy is particularly strongly recommended to protect bone, cardiovascular, and neurological health until the average age of natural menopause
• Women with significant GSM — vaginal dryness, dyspareunia, recurrent UTIs
• Women with menopause-related mood disturbances — particularly during perimenopause
• Women with elevated osteoporosis risk requiring bone protection

Who Should Avoid or Use Caution With Hormone Therapy

Hormone therapy requires individualized assessment and may not be appropriate for women with:

• Personal history of hormone-receptor-positive breast cancer (typically a contraindication to systemic HT — discuss with your oncologist)
• Personal history of venous thromboembolism (blood clots) — transdermal estrogen has a much lower clot risk than oral; may still be an option in selected cases
• Personal history of stroke or heart attack — particularly if recent
• Active or recent liver disease
• Unexplained vaginal bleeding — must be evaluated before initiating HT
• Known or suspected endometrial or breast cancer

Non-Hormonal Options: When Hormone Therapy Is Not Appropriate

For women who cannot or choose not to use hormone therapy, several non-hormonal options have evidence supporting their use:

FDA-Approved Non-Hormonal Options:

• Fezolinetant (Veozah) — a selective neurokinin 3 (NK3) receptor antagonist, the first non-hormonal drug specifically approved for moderate-to-severe vasomotor symptoms (2023). Clinical trials published in JAMA (2023) found it significantly reduced hot flash frequency and severity
• SSRIs and SNRIs (paroxetine, venlafaxine, desvenlafaxine) — modest efficacy for hot flashes, with the added benefit of addressing mood symptoms
• Gabapentin — effective for nighttime hot flashes and sleep disruption
• Clonidine — modest vasomotor benefit with blood-pressure-lowering effects

Lifestyle Approaches with Evidence:

• Cognitive behavioral therapy (CBT) — shown in multiple RCTs to significantly reduce the perceived impact of hot flashes and improve sleep and mood
• Mindfulness-based stress reduction (MBSR)
• Regular aerobic exercise — associated with reduced vasomotor symptom severity and improved sleep and mood
• Dietary modification — reducing caffeine, alcohol, and spicy foods as common hot flash triggers; increasing phytoestrogen-rich foods (soy, flaxseed)
• Acupuncture — modest evidence for vasomotor symptom reduction

The “Timing Window”: Why Starting Hormone Therapy Earlier May Be Better

One of the most important recent insights in menopause medicine is that the timing of HT initiation relative to menopause onset significantly affects outcomes  for both symptom relief and long-term health.

The “window of opportunity” concept, supported by the ELITE trial (published in New England Journal of Medicine, 2016), demonstrated that:

• Women who began estradiol therapy within 6 years of menopause showed significantly less progression of subclinical atherosclerosis (arterial wall thickening) compared to placebo
• Women who began estradiol therapy more than 10 years after menopause showed no cardiovascular benefit from therapy

This finding has profound clinical implications: women who initiate HT early in the menopausal transition not only achieve the best symptom relief but may also receive the greatest long-term cardiovascular and neuroprotective benefit. Waiting until symptoms become intolerable or delaying treatment out of unfounded fear may forfeit these protective effects.

Frequently Asked Questions About Hormone Therapy for Menopause

Is hormone therapy safe? For the majority of healthy women under 60 and within 10 years of menopause, the benefits of hormone therapy for significant symptoms substantially outweigh the risks. The key is individualized assessment of your personal medical history, risk factors, and preferences all matter. This is a conversation to have with an experienced women’s health provider who can evaluate your complete picture.

How long can I take hormone therapy? There is no arbitrary time limit on hormone therapy for women whose benefits continue to outweigh risks. The Menopause Society’s 2022 position statement states that duration should be based on individual risk-benefit assessment, not a preset number of years. Many women take HT well into their 60s with appropriate monitoring.

Will stopping hormone therapy make menopause symptoms come back? Yes for many women, vasomotor symptoms return after discontinuing HT, sometimes quite abruptly. Tapering the dose gradually rather than stopping suddenly tends to minimize symptom recurrence.

What is the best form of hormone therapy? There is no universally “best” form of the optimal regimen depending on your symptoms, health history, and preferences. Transdermal delivery is generally preferred for its lower clot risk and stable blood levels. Micronized progesterone is increasingly preferred for its favorable safety profile. Your provider will individualize your regimen.

Can hormone therapy help with weight gain during menopause? While HT does not produce weight loss per se, evidence suggests it helps reduce the shift in fat distribution toward the abdomen (visceral adiposity) that occurs after menopause, a change linked to increased metabolic and cardiovascular risk. Combined with a healthy diet and exercise, HT supports a healthier metabolic profile.

Can I take hormone therapy if I have a family history of breast cancer? Family history alone is not necessarily a contraindication to HT, though it warrants careful discussion and risk assessment. Women with BRCA1/2 mutations require individualized consultation. This is an important conversation to have with your provider.

The Bottom Line: Informed Choices Transform the Menopause Experience

Menopause is inevitable. Suffering through it without treatment, accepting years of disrupted sleep, relentless hot flashes, painful intercourse, mood instability, and bone loss as an unavoidable rite of passage, is not.

Hormone therapy, when initiated at the right time, in the right dose, via the right route, and with appropriate monitoring, is the most effective intervention available for menopause symptoms, with meaningful protective effects on bone, cardiovascular health, and cognitive function that extend far beyond symptom relief.

The decision to use hormone therapy should be made in collaboration with a knowledgeable, current women’s health provider who takes the time to understand your full health picture, your symptoms, your values, and your goals and who stays abreast of the evolving science.

You deserve that conversation. And you deserve the quality of life that modern menopause medicine can provide.

Are you navigating the changes of perimenopause or menopause and wondering if hormone therapy is right for you? At IVANA MD, our experienced and compassionate women’s health team provides comprehensive menopause evaluations, personalized hormone therapy consultations, and individualized treatment plans designed around your symptoms, your health history, and your life goals.

Whether you are just beginning to notice changes or have been struggling with menopause symptoms for years, we are here to give you the expert, evidence-based, and deeply personal care you deserve.

Your menopause. Your health. Your choice — supported by expert care.

Schedule Your Women’s Health Appointment with IVANA MD

Call: 346-585-4077

4220 Cartwright Road, Suite 201, Missouri City, Texas 77459

This blog is intended for educational and informational purposes only and does not constitute medical advice. Always consult a qualified women’s health provider before initiating, changing, or discontinuing hormone therapy.

References

1. The Menopause Society (formerly NAMS). (2022). The 2022 Menopause Society Hormone Therapy Position Statement. Menopause, 29(7), 767–794. https://doi.org/10.1097/GME.0000000000002028
2. Hamoda, H., Mukherjee, A., Morris, E., Baldeweg, S. E., Jayasena, C. N., Briggs, P., & ”Shandley, L. (2020). Joint British Menopause Society and British Menopause Society consensus statement on the use of hormone replacement therapy in perimenopausal women. Post Reproductive Health, 26(3), 119–124. https://doi.org/10.1177/2053369120957514
3. MacLennan, A. H., Broadbent, J. L., Lester, S., & Moore, V. (2004). Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database of Systematic Reviews, (4), CD002978. https://doi.org/10.1002/14651858.CD002978.pub2
4. Rossouw, J. E., Prentice, R. L., Manson, J. E., Wu, L., Barad, D., Barnabei, V. M., … & Stefanick, M. L. (2007). Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA, 297(13), 1465–1477. https://doi.org/10.1001/jama.297.13.1465
5. Hodis, H. N., Mack, W. J., Henderson, V. W., Shoupe, D., Budoff, M. J., Hwang-Levine, J., … & Selzer, R. H. (2016). Vascular effects of early versus late postmenopausal treatment with estradiol. New England Journal of Medicine, 374(13), 1221–1231. https://doi.org/10.1056/NEJMoa1505241
6. Cauley, J. A., Robbins, J., Chen, Z., Cummings, S. R., Jackson, R. D., LaCroix, A. Z., … & Watts, N. B. (2003). Effects of estrogen plus progestin on risk of fracture and bone mineral density. JAMA, 290(13), 1729–1738. https://doi.org/10.1001/jama.290.13.1729
7. Collaborative Group on Hormonal Factors in Breast Cancer. (2019). Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. The Lancet, 394(10204), 1159–1168. https://doi.org/10.1016/S0140-6736(19)31709-X
8. Cohen, L. S., Soares, C. N., Vitonis, A. F., Otto, M. W., & Harlow, B. L. (2006). Risk for new onset of depression during the menopausal transition: the Harvard study of moods and cycles. Archives of General Psychiatry, 63(4), 385–390. https://doi.org/10.1001/archpsyc.63.4.385
9. Gordon, J. L., Rubinow, D. R., Eisenlohr-Moul, T. A., Xia, K., Schmidt, P. J., & Girdler, S. S. (2018). Efficacy of transdermal estradiol and micronized progesterone in the prevention of depressive symptoms in the menopause transition. JAMA Psychiatry, 75(2), 149–157. https://doi.org/10.1001/jamapsychiatry.2017.3998
10. El Khoudary, S. R., Aggarwal, B., Beckie, T. M., Hodis, H. N., Johnson, A. E., Langer, R. D., … & Ylitalo, K. R. (2020). Menopause transition and cardiovascular disease risk: implications for timing of early prevention. Circulation, 142(25), e506–e532. https://doi.org/10.1161/CIR.0000000000000912
11. Freeman, E. W., Sammel, M. D., Lin, H., & Nelson, D. B. (2006). Associations of hormones and menopausal status with depressed mood in women with no history of depression. Archives of General Psychiatry, 63(4), 375–382. https://doi.org/10.1001/archpsyc.63.4.375
12. Nappi, R. E., & Kokot-Kierepa, M. (2012). Vaginal Health: Insights, Views & Attitudes (VIVA) — results from an international survey. Climacteric, 15(1), 36–44. https://doi.org/10.3109/13697137.2011.647840
13. Writing Group for the Women’s Health Initiative Investigators. (2002). Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA, 288(3), 321–333. https://doi.org/10.1001/jama.288.3.321
14. Anderson, G. L., Limacher, M., Assaf, A. R., Bassford, T., Beresford, S. A., Black, H., … & Stefanick, M. L. (2004). Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. JAMA, 291(14), 1701–1712. https://doi.org/10.1001/jama.291.14.1701
15. Fournier, A., Fabre, A., Mesrine, S., Boutron-Ruault, M. C., Berrino, F., & Clavel-Chapelon, F. (2008). Use of different postmenopausal hormone therapies and risk of histology- and hormone receptor–defined invasive breast cancer. Journal of Clinical Oncology, 26(8), 1260–1268. https://doi.org/10.1200/JCO.2007.13.4338
16. Shifren, J. L., Gass, M. L. S., & NAMS Recommendations for Clinical Care of Midlife Women Working Group. (2014). The North American Menopause Society recommendations for clinical care of midlife women. Menopause, 21(10), 1038–1062. https://doi.org/10.1097/GME.0000000000000319
17. Stuenkel, C. A., Davis, S. R., Gompel, A., Lumsden, M. A., Murad, M. H., Pinkerton, J. V., & Santen, R. J. (2015). Treatment of symptoms of the menopause: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology & Metabolism, 100(11), 3975–4011. https://doi.org/10.1210/jc.2015-2236
18. Neal-Perry, G., Venkat, A., Osman, H., Syms, C., Kaur, R., Bhatt, A., … & Pinkerton, J. V. (2023). Efficacy and safety of fezolinetant in moderate-to-severe vasomotor symptoms associated with menopause: a randomized controlled trial. JAMA, 329(13), 1093–1103. https://doi.org/10.1001/jama.2023.4086